Weiping Jia

Shanghai University, Shanghai, Shanghai Shi, China

Are you Weiping Jia?

Claim your profile

Publications (201)903.33 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study was designed to determine the prevalence of 'metabolically healthy but obese' (MHO) and 'metabolically abnormal but not obese' (MANO) phenotypes in Chinese population, and to investigate the association of these two phenotypes with the risk of diabetes and cardiovascular disease (CVD). A total of 2,764 subjects aged 30-90 were followed up over a mean period of 43.80 ± 11.25 months. The metabolic syndrome was defined according to the joint committee for developing Chinese guidelines on prevention and treatment of dyslipidemia in adults. Subjects with body fat percentage (BF %) >25 % for men or BF % >35 % for women were defined as being obese. The proportion of MHO and MANO phenotypes were 22.9, 7.6 % in men, and 26.2, 6.0 % in women, respectively. The MANO phenotype was associated with increased risk for diabetes both in men [hazard ratios (HR): 4.44 (1.21-16.26)] and women [HR: 8.68 (2.87-24.96)] after adjustment of age, serum total cholesterol (TC), triglycerides (TG), and family history of diabetes. This association held for CVD in women [HR: 2.87 (1.44-5.73)], but not in men after adjustment of age, serum TC, TG, and family history of CVD. No association was observed between the MHO phenotype and incident diabetes or CVD. MHO and MANO phenotypes are common in Chinese population. Metabolic risk factors appeared to play a more important role in the development of diabetes and CVD than body fat alone.
    Endocrine. 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: BackgroundsWe hypothesize that depression in type 2 diabetes might be associated with poor glycemic control, in part due to suboptimalself-care. We tested this hypothesis by examining the associations of depression with clinical and laboratory findingsin a multicenter survey of Chinese type 2 diabetic patients.Method2538 patients aged 18-75 yearsattending hospital-based clinics in fourcities in China underwent detailed clinical-psychological-behavioral assessment during a 12-month periodbetween 2011 and 2012. Depression was diagnosed if Patient Health Questionnaire-9(PHQ-9) score≥10.Diabetes self-care and medication adherence were assessed using the Summary of Diabetes Self-care Activities and the 4-item Morisky medication adherence scale respectively.ResultsIn this cross-sectional study (mean age: 56.4±10.5[SD] years, 53% men), 6.1%(n=155) had depression. After controlling for study sites, patients with depression had higher HbA1c(7.9±2.0vs. 7.7±2.0%, P=0.008) and were less likely to achieve HbA1c goal of <7.0%(36.2% vs. 45.6%, P=0.004)than those without depression. They were more likely to report hypoglycemia and to have fewer days ofbeing adherent to their recommended diet, exercise, foot care and medication. In logistic regression, apart from young age, poor education, long disease duration, tobacco use,high body mass index,use of insulin, depression was independently associated with failure to attain HbA1c target(Odds Ratio[OR]=1.56, P=0.028). The association between depression and glycemic control became non-significant after inclusion of adherence to diet, exerciseand medication(OR=1.48, P=0.058).Conclusion Depression in type 2 diabetes was closely associated with hyperglycemiaandhypoglycemia which might be partly mediated through poor treatment adherence.
    Journal of Diabetes 10/2014; · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of cardiovascular diseases (CVD). Lipocalin-2 (LCN2), mainly released from adipocytes, has been shown to be positively associated with CVD in cross-sectional studies. We aimed to evaluate the association of LCN2 with CVD involving a population-based cohort recruited from the Shanghai Diabetes Study.
    Arteriosclerosis Thrombosis and Vascular Biology 09/2014; · 6.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective: Serum cystatin C is a sensitive marker of kidney function and recent studies have shown that cystatin C plays a critical role in degenerative diseases of both central and peripheral nervous systems. The aim of this study was to explore the relationship between serum cystatin C and diabetic peripheral neuropathy (DPN) in type 2 diabetes. Methods: Totally 937 type 2 diabetic patients were enrolled in this cross-sectional study. Serum cystatin C concentration was measured with immunoturbidimetry. DPN was evaluated by neurological symptoms, neurological signs, neurothesiometer and electromyogram. Results: Serum cystatin C levels were significantly higher in DPN patients [1.3(1.1-1.5)mg/L] compared with signs of DPN[1.1(0.9-1.3)mg/L, p<0.001] and non-DPN patients (1.0(0.9-1.3)mg/L, p<0.001). Multiple regression analysis revealed that DPN was associated with age, diabetes duration, glycosylated hemoglobin A1c(HbA1c) and serum cystatin C. Spearman correlation analysis showed that serum CysC was closely related to age, sex, diabetes duration, hypertension, glomerular infiltration rate and serum creatinine. Patients were divided into quartiles according to the serum cystatin C levels. Compared with Quartile1(referent), the risk of DPN was significantly higher in Quartile2(OR, 1.753; 95%CI 1.055-2.912; p<0.05), Quartile3(OR, 2.463; 95%CI 1.445-4.917; p<0.01) and Quartile4(OR, 5.867; 95%CI 2.075-16.589; p<0.01). Receiver operating characteristic analysis revealed that the optimal cutoff point of serum cystatin C to indicate DPN was 1.25mg/L in male patients and 1.05mg/L in female patients. And high serum cystatin C indicated double risk of DPN. Conclusions: High serum cystatin C is closely associated with DPN and may be a potential biomarker for DPN in type 2 diabetes.
    European journal of endocrinology / European Federation of Endocrine Societies. 09/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acetaminophen (APAP) overdose is a leading cause of drug‐induced hepatotoxicity and acute liver failure worldwide, but its pathophysiology remains incompletely understood. Fibroblast growth factor 21 (FGF21) is a hepatocyte‐secreted hormone with pleiotropic effects on glucose and lipid metabolism. This study aimed to investigate the pathophysiological role of FGF21 in APAP‐induced hepatotoxicity in mice. In response to APAP overdose, both hepatic expression and circulating levels of FGF21 in mice were dramatically increased as early as 3 hours, prior to elevations of the liver injury markers alanine aminotransferase (ALT) and aspartate aminotransferase (AST). APAP overdose‐induced liver damage and mortality in FGF21 knockout (KO) mice were markedly aggravated, which was accompanied by increased oxidative stress and impaired antioxidant capacities as compared to wild‐type (WT) littermates. By contrast, replenishment of recombinant FGF21 largely reversed APAP‐induced hepatic oxidative stress and liver injury in FGF21 KO mice. Mechanistically, FGF21 induced hepatic expression of peroxisome proliferator‐activated receptor coactivator protein‐1α (PGC‐1α), thereby increasing the nuclear abundance of nuclear factor erythroid 2‐related factor 2 (Nrf2) and subsequent up‐regulation of several antioxidant genes. The beneficial effects of recombinant FGF21 on up‐regulation of Nrf2 and antioxidant genes and alleviation of APAP‐induced oxidative stress and liver injury were largely abolished by adenovirus‐mediated knockdown of hepatic PGC‐1α expression, whereas overexpression of PGC‐1α was sufficient to counteract the increased susceptibility of FGF21 KO mice to APAP‐induced hepatotoxicity. Conclusion: The marked elevation of FGF21 by APAP overdose may represent a compensatory mechanism to protect against the drug‐induced hepatotoxicity, by enhancing PGC‐1α/Nrf2‐mediated antioxidant capacity in the liver. (Hepatology 2014;60:977–989)
    Hepatology 09/2014; 60(3). · 12.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have identified that several amino acids, in particular, branched-chain amino acids (BCAAs), increased significantly in obese compared with lean individuals. Additionally, these metabolites were strongly associated with future diabetes, rendering them prognostic markers suitable for obese populations. Here we report a metabonomic study that reveals new findings on the role of these amino acid markers, particularly BCAAs, in a Chinese cohort including 106 healthy obese and 105 healthy lean participants. We found that the BCAAs were correlated with insulin resistance and differentially expressed in obese men, but not in obese women. The results were verified with two independent groups of participants (Chinese, n=105 and American, n=72), demonstrating that the serum metabolite profiles of the obese population are gender-dependent. The study supports the previous findings of a panel of several key metabolites as prognostic markers of obese population, and highlights the need to take into account gender differences when using these markers for risk assessment.
    Journal of Proteome Research 08/2014; · 5.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Recent studies highlight a critical interaction between adipocyte fatty acid binding protein (A-FABP) and cardiovascular disorders. However, associations of A-FABP with subclinical atherosclerosis in a population with normal glucose tolerance remain unknown. Objectives: The study aimed to evaluate the relationship between A-FABP and carotid intima-media thickness (C-IMT) in a Chinese population with normal glucose tolerance. Design/setting/participants: A cross-sectional analysis was conducted of 2253 cardiovascular disease-free normal glucose tolerance subjects (835 men, 1418 women; 20-78 years old) from the Shanghai Obesity Study. Main outcome and measures: C-IMT was measured by B-mode ultrasound and used to assess subclinical atherosclerosis. Serum A-FABP levels were quantified by a sandwich enzyme-linked immunosorbent assay. Results: The median serum level for A-FABP was 4.0 ng/mL (interquartile range: 2.6-6.0 ng/mL), and significantly higher in women than men (P < 0.001). After adjusting for age and body mass index (BMI), a partial correlation analysis showed that A-FABP levels correlated with C-IMT in men, premenopausal and postmenopausal women (P = 0.024, 0.006, and 0.016, respectively). Furthermore, C-IMT increased along with quartile A-FABP values (all P for trend < 0.001). Regression analyses demonstrated that A-FABP was associated with C-IMT only in women (P = 0.044 and 0.001 for pre- and postmenopausal, respectively). Moreover, A-FABP was identified as a risk factor for C-IMT in pre- and postmenopausal women with a normal BMI (P < 0.001 and P = 0.012, respectively). Conclusions: Serum A-FABP levels independently and positively correlate with subclinical atherosclerosis in pre- and postmenopausal Chinese women with normal glucose tolerance after adjustments for the traditional risk factors.
    The Journal of clinical endocrinology and metabolism. 08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Toll-like receptor 4 (TLR4) plays an important role in innate immunity. Activation of innate immune response and subsequent chronic low-grade inflammation are thought to be involved in the pathogenesis of type 2 diabetes. In this study, we aimed to investigate the association of TLR4 variants with type 2 diabetes in the Chinese population.Methods Seven tag single nucleotide polymorphisms (SNPs) of TLR4 based on HapMap Chinese data were genotyped in the Shanghai Chinese, including 3404 type 2 diabetes patients and 3401 controls. The controls were extensively phenotyped for the traits related to glucose metabolism and insulin secretion.ResultsIn total participants, we identified that rs10759932 and rs1927911 were associated with type 2 diabetes (odds ratio 1.106, P = 0.009 for rs10759532, odds ratio 1.092, P = 0.013 for rs1927911). rs11536889 showed a trend association with type 2 diabetes (odds ratio 0.957, P = 0.057). This SNP was also associated with 2-h plasma glucose (P = 0.033) and HDL-cholesterol (P = 0.031). In female participants, rs10759932, rs1927911 and rs11536889 were associated with type 2 diabetes (odds ratio 1.176, P = 0.002 for rs10759932, odds ratio 1.136, P = 0.009 for rs1927911, odds ratio 0.882, P = 0.024 for rs11536889). Besides, rs11536889 was significantly associated with 2-h plasma glucose (P = 0.050) and HOMA-B (P = 0.046) with adjusting for age and BMI in female normal subjects.Conclusions We conclude that genetic variants of TLR4 are associated with type 2 diabetes in the Chinese population, especially in female subjects.
    Journal of Diabetes 08/2014; · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to investigate the effect of the potassiumInwardly rectifying channel, subfamily J, member 11 (KCNJ11) E23K variant on gliclazide-modified release (gliclazide MR) treatment in newly diagnosed patients with type 2 diabetes mellitus (T2DM). A total of 108 diabetic patients with no history of antidiabetic medication were treated with gliclazide MR for 16 weeks and underwent follow-up at weeks 2, 4, 8, 12, and 16. KCNJ11 E23K (rs5219) was genotyped in all patients. At baseline, the patients with KK displayed higher blood glucose and lower serum insulin levels after oral glucose administration than those with EE and EK (all P < 0.05). During the treatment, individuals with KK exhibited lower fasting glucose levels and were more likely to attain the standard fasting glucose level (Plog-rank = 0.028) than the E allele carriers. Patients with a greater number of 23K showed larger augmentations in Δacute insulin response (P = 0.049) and Δbody mass index (BMI) levels (P = 0.003). Moreover, patients with EK had a lower variance in the changes in fasting insulin levels (P = 0.049) and homeostasis model assessment of β-cell function (ΔHOMA–β, P = 0.021) than those with KK. The findings of the present study suggest that KCNJ11 E23K is associated with the greater effect of sulfonylurea treatment in newly diagnosed Chinese patients with T2DM.This article is protected by copyright. All rights reserved.
    Clinical and Experimental Pharmacology and Physiology 08/2014; · 2.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of diabetes is increasing in young adults in Asia, but little is known about metabolic control or the burden of associated complications in this population. We assessed the prevalence of young-onset versus late-onset type 2 diabetes, and associated risk factors and complication burdens, in the Joint Asia Diabetes Evaluation (JADE) cohort.
    The lancet. Diabetes & endocrinology. 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Disulfide-bond A Oxidoreductase-like protein (DsbA-L) possesses beneficial effects such as promoting adiponectin multimerization and stability, increasing insulin sensitivity, and enhancing energy metabolism. The expression level of DsbA-L is negatively correlated with obesity in mice and humans, but the underlying mechanisms remain unknown. To address this question, we generated reporter gene constructs containing the promoter sequence of the mouse DsbA-L gene. Deletion analysis showed that the proximal promoter of mouse DsbA-L is located between -186 to -34 bp relative to the transcription start site. In silico analysis identified a putative Sp1 transcription factor binding site in the first intron of DsbA-L gene. Electrophoretic mobility shift assay and chromatin immunoprecipitation analysis indicated that Sp1 bound to this intron region in vitro and in intact cells. Overexpression of Sp1 or suppressing Sp1 expression by siRNA reduced or increased DsbA-L promoter activity, respectively. The binding activity of Sp1 was gradually decreased during 3T3-L1 cells differentiation, and was significantly increased in adipose tissues of obese mice. Our results identify Sp1 as an inhibitor of DsbA-L gene transcription and the Sp1-mediated inhibition of DsbA-L gene expression may provide a mechanism underlying obesity-induced adiponectin down-regulation and insulin resistance.
    Diabetes 07/2014; · 7.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Type 2 diabetes (T2D) increases the risk of cardiovascular disease (CVD). Achieving glycated hemoglobin (HbA1c) below 7.0 % in newly diagnosed T2D reduced CVD risk. It is uncertain whether HbA1c below 7.0 % in T2D with varying duration of diabetes also reduced CVD risk. This study investigated the associations between hyperglycemia and abnormal lipid metabolism in patients with T2D. Methods We conducted a survey of 19,757 outpatients with T2D who were 18 years of age or more and treated with oral antidiabetes drugs (OADs) alone or OADs combined with other drugs. The coverage rates of the 3A hospitals were 74.4 % for Beijing (n = 32), 76 % for Shanghai (n = 22), 55 % for Tianjin (n = 11) and 29.3 % for Guangzhou (n = 12). Abnormal lipids were defined as ≥2.6 mmol/L for low-density lipoprotein (LDL) cholesterol, ≤1.0 mmol/L in men and ≤1.3 mmol/L in women for high-density lipoprotein (HDL) cholesterol; ≥1.7 mmol/L for triglyceride. Logistic regression stratified on city and hospital was used to obtain odds ratio (OR) of hyperglycemia for abnormal lipids. Results The patients had 4.0 (interquartile range 1.7–8.8) years of duration of diabetes. HbA1c ≥7.0 % was associated with increased risk of high LDL cholesterol (multivariable OR of ≥7.0 vs. <6.0 %:1.37, 95 % confidence interval 1.19–1.57). HbA1c ≥6.5 % was associated increased risk of high triglyceride. HbA1c was associated with low HDL cholesterol in a J-shaped manner, whereby HbA1c levels of <6.0 % as well as ≥6.5 % being associated with increased risk of low HDL cholesterol. Conclusions Hyperglycemia defined as HbA1c ≥7.0 % increased risk of high LDL cholesterol in T2D.
    Journal of endocrinological investigation 06/2014; · 1.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the relationship between selenoprotein P (SEPP) and insulin resistance in subjects with normal glucose tolerance and type 2 diabetes mellitus.
    Zhonghua yi xue za zhi. 06/2014; 94(22):1710-3.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the effects of metformin therapy on serum carbohydrate antigen 125 (CA125) levels and its related factors in type 2 diabetics with normal liver and kidney function.
    Zhonghua yi xue za zhi. 05/2014; 94(18):1380-3.
  • Cell Research 05/2014; · 10.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To investigate the current status of oral anti-diabetic drug (OAD) therapy in patients with type 2 diabetes and influencing factors in real-world setting in China.Methods9,872 outpatients with type 2 diabetes, who had received OADs (monotherapy or combination therapy) for at least 3 months were recuited in this study. Current antidiabetic treatment regimen and related clinical data were collected from medical records and analyzed.ResultsThe most common OADs in use were insulin secretagogues (70.2%) such as sulfonylureas (SUs; 42.7%) or glinides (27.5%), followed by metformin (53.7%), α-glucosidase inhibitors (35.9%), thiazolidinediones (17.2%), and dipeptidyl peptidase-4 (DPP-4) inhibitors (0.8%). Dual-drug combination therapy was more common (45.4%) than monotherapy (35.8%) and combination therapy with at least 3 drugs (17.0%). Patients on SU or glinide monotherapy were more likely to alter their treatment frequently (odds ratio [OR], 1.7; 95% CI, 1.38-2.08; P <.001).Conclusions The status of OAD used in China is varied with a majority of the patients altering their treatment regimen citing poor effectiveness. These observations from a real-world setting may serve as guidance for improving diabetes management in China.·Significant findings of the study: We observed that monotherapy with metformin was associated with lower hypoglycemic events and lower treatment alterations than monotherapy with other drugs, while the frequency of the treatment alterations, poor glycemic control, and hypoglycemia was higher in patients receiving insulin secretagogues.·What this study adds: The frequency of treatment alterations was inversely associated with glycemic target achievement.
    Journal of Diabetes 05/2014; · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: This study investigated the performance of the A1CNow(+®) test (Bayer Diabetes Care, Sunnyvale, CA) in a large population of Chinese patients with diabetes. Subjects and Methods: Hemoglobin A1c (HbA1c) levels in 1,618 Chinese patients with diabetes 10-94 years of age were measured with both the A1CNow(+) test, from a fingerstick blood sample, and the high-performance liquid chromatography (HPLC) test, using a venous blood sample, within 24 h. The reportable ranges of the HbA1c values were 4.0-13.0% (A1CNow(+)) and 4.1-16.8% (HPLC). An error grid analysis (EGA) method was developed to quantify the accuracy of the A1CNow(+) results against the HPLC reference results. Results: The A1CNow(+) results were highly correlated with the HPLC reference results (r=0.945, P<0.01). Passing-Bablok regression analysis showed a good linear agreement between the two variables, and the linear regression equation fitted as y=-0.10+1.00x (P=0.21). The Bland-Altman difference plot presented that the mean bias of the A1CNow(+) results minus the HPLC reference results was -0.09% (P<0.001); the 95% confidence intervals for the limits of agreement were -1.28% to 1.09%, with 96.5% of the data points lying within this zone. The results of the EGA showed that 80.2% of the A1CNow(+) results were accurate, 17.7% were acceptable, 1.9% may lead to inappropriate treatment, and 0.3% may lead to severe clinical consequence. Conclusions: The A1CNow(+) test values demonstrated a slight negative bias from the HPLC values. The majority of A1CNow(+) test values were accurate when compared with results from the reference method.
    Diabetes Technology &amp Therapeutics 04/2014; · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of the study was to determine whether impaired beta-cell function exists in Chinese individuals within the normal range of glucose tolerance (NGT), and these individuals are predisposed to diabetes later in life. The cross-sectional study included 843 NGT subjects and 562 isolated impaired glucose tolerance (IGT) patients and the longitudinal study included 1,724 NGT subjects. Insulin secretion was assessed using indices derived from oral glucose tolerance test and adjusted by insulin resistance. NGT subjects were sub-divided into two groups: NGT-l (2hPG < 125 mg/dl) and NGT-h (2hPG 125-140 mg/dl). Normal weight subjects were individuals with BMI < 25 kg/m(2), and overweight were with BMI ≥ 25 kg/m(2). In normal weight subjects, the first- and second-phase insulin secretion indices were significantly higher in NGT-h and NGT-l subjects compared with IGT subjects. However, in overweight subjects, first-phase insulin secretion index in NGT-h subjects was significantly lower than that in NGT-l subjects, but similar to that in IGT patients. The second-phase insulin secretion was comparable between NGT-h and NGT-l subjects. After an average follow-up of 43.80 ± 11.25 months, totally 25 (1.5 %) NGT subjects at baseline developed diabetes. The incidence rate of diabetes was higher in NGT-h overweight subjects (9.2 %) than in NGT-l overweight subjects (1.5 %) with a risk ratio (RR) reaching 6.655 [95 % confidence interval (CI) 2.347-18.867]. This risk remained after adjustment for sex, age, BMI, systolic pressure, and diastolic pressure (RR 8.315, 95 % CI 2.649-26.108). It is concluded that overweight NGT adults with high-normal 2hPG (≥125 mg/dl) had a defect in first-phase insulin secretion and were with the increasing risk for developing new diabetes.
    Endocrine 04/2014; · 1.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have demonstrated a protective effect of osteocalcin (OCN) on glucose homeostasis and metabolic syndrome. However, its role in vascular function remains unknown. This study investigated the contribution of OCN to the pathogenesis of endothelial dysfunction in the thoracic aorta of apolipoprotein E-deficient (ApoE-KO) mice. Eight-week-old ApoE-KO mice were given chow or high fat diet (HFD) for 12 weeks with or without daily intraperitoneal injection of OCN. Intraperitoneal glucose tolerance test (IPGTT),insulin tolerance test (ITT),measurement of serum lipid profiles and blood pressure were carried out. Endothelium-dependent relaxation (EDR) was measured by wire myography. Human umbilical vein endothelial cells (HUVECs) were used to study the role of OCN on eNOS levels in vitro. PI3K inhibitor (LY294002) and Akt inhibitor V were used ex-vivo to determine whether PI3K/Akt/eNOS contributes to the beneficial effect of OCN for the vascular or not. Daily injections of OCN can significantly improve lipid metabolism, glucose tolerance and insulin sensitivity in ApoE-KO mice. In ApoE-KO mice fed with HFD, the OCN-treated mice displayed an improved acetylcholine-stimulated EDR compared to the vehicle-treated group. In addition, compared to vehicle-treated HUVECs, OCN-treated HUVECs displayed increased activation of the Akt-eNOS signaling pathway, as evidenced by significantly higher levels of phosphorylated Akt and eNOS. Furthermore, a similar beneficial effect of OCN on thoracic aorta was observed using ex vivo organ culture of isolated mouse aortic segment. However, this effect was attenuated upon co-incubation with PI3K inhibitor or Akt inhibitor V. Our study demonstrates that OCN has an endothelial-protective effect in atherosclerosis through mediating the PI3K/Akt/eNOS signaling pathway.
    Cardiovascular Diabetology 04/2014; 13(1):74. · 4.21 Impact Factor
  • Weiping Jia
    The lancet. Diabetes & endocrinology. 04/2014; 2(4):e6-7.

Publication Stats

3k Citations
903.33 Total Impact Points

Top co-authors View all


  • 2014
    • Shanghai University
      Shanghai, Shanghai Shi, China
  • 2008–2014
    • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      Shanghai, Shanghai Shi, China
  • 2007–2014
    • Shanghai Clinical Research Center
      Shanghai, Shanghai Shi, China
    • Shanghai Jiao Tong University
      • • School of Pharmacy
      • • Department of Pediatrics (Sixth People's Hospital)
      Shanghai, Shanghai Shi, China
  • 2013
    • China-Japan Friendship Hospital
      Peping, Beijing, China
    • Henan Provincial People’s Hospital
      Cheng, Henan Sheng, China
  • 2012
    • Soochow University (PRC)
      Wu-hsien, Jiangsu Sheng, China
    • Shanghai University of Traditional Chinese Medicine
      Shanghai, Shanghai Shi, China
    • The University of Hong Kong
      • Department of Medicine
      Hong Kong, Hong Kong
  • 2002–2012
    • Shanghai Cancer Institute
      Shanghai, Shanghai Shi, China
  • 2006–2009
    • University of Oxford
      • • Wellcome Trust Centre for Human Genetics
      • • Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM)
      Oxford, ENG, United Kingdom